Platforms helping covered entities internalise programme dispensing, manage referral capture and optimise revenue — structurally insulated from manufacturer contract-pharmacy restrictions.
Home health, hospice and post-acute operations serving aging populations and the hospital-at-home shift — fragmented, durably reimbursed, built for consolidation.
AI-native platforms automating denials, charge capture, clinical documentation and prior authorisation, with 12–24 month payback periods.
Within 90 days of close we run an aggressive operational reset — vendor renegotiation, procurement, staffing and billing — in the first quarter, not the first year.
Structured BD and sales playbooks from C-suite roles scaling companies from zero to billions.
Unit economics, operating expense rationalisation and procurement leverage inside 18 months.
Materials are released only to verified accredited investors. Nothing on this page is an offer to sell securities.
A working product with a consistent customer base and a robust pipeline — with selective exposure to earlier rounds where the operating thesis is unusually clear.
We look at proven companies in any large market our experience compounds in — healthcare services and health technology, and equally technology, consumer, media and wellness.
Management with a history of success, including women-led businesses. We back operators, because we are operators.
Platforms helping covered entities internalise programme dispensing, manage referral capture and optimise revenue — structurally insulated from manufacturer contract-pharmacy restrictions.
Home health, hospice and post-acute operations serving aging populations and the hospital-at-home shift — fragmented, durably reimbursed, built for consolidation.
AI-native platforms automating denials, charge capture, clinical documentation and prior authorisation, with 12–24 month payback periods.
CMS and payers are migrating to value-based, site-neutral care — creating durable revenue predictability and multi-year exit visibility.
Automation now generates 12–24 month payback periods, making RCM platforms immediate acquisition targets for EHR systems and strategic buyers.
Lower-middle-market assets are highly fragmented — institutional rollups command 12–15x exit multiples against 7–9x entry.
In-home dispensing, polypharmacy capture and shared referral pipelines compound per-patient revenue across both.
AI-native revenue cycle deployed portfolio-wide — margin expansion, denials capture and exit value in every vertical.
Care networks feed geographic referral pipelines, patient continuity and polypharmacy capture back into platform growth.
MSO and ACO infrastructure lets portfolio companies win and retain value-based contracts, increasing revenue predictability and exit attractiveness to payers and health systems.
Within 90 days of close we run an aggressive operational reset — vendor renegotiation, procurement, staffing and billing — in the first quarter, not the first year.
Structured BD and sales playbooks from C-suite roles scaling companies from zero to billions.
Unit economics, operating expense rationalisation and procurement leverage inside 18 months.
Pamela has over 20 years of operations, capital raising, merger and acquisition strategy, marketing positioning and business development experience across health and wellness, SaaS and IT infrastructure, mobile device technology, entertainment and digital media, and financial services and fintech. Her clients have been featured on 60 Minutes, Oprah and the Today Show, and on the covers of BusinessWeek, Fast Company and Inc. Magazine.
She launched the first-ever general purpose prepaid card, growing customer deposits from zero to $2+ billion in three years through partnerships with Visa, NBC Universal, Gateway Computers, Jackson-Hewitt and Intuit. She led the media and marketing launch of ExpertVillage, acquired within fifteen months by Demand Media, and launched large-scale programmes with Kaiser, Independence Blue Cross and Universal American.
Pamela was most recently COO at Fastlane, where she ran the firm's investor strategy and readiness arm as well as marketing positioning for M&A within large market-leading clients.
Robert has been CEO of technology, media, energy, environmental and healthcare companies, and has raised or managed over $750 million in deals, financings, acquisitions and exits with companies including Allen & Co., Merrill Lynch, Citigroup, Omnicom, Oppenheimer, Hewlett Packard, Verizon and Samsung.
He founded and was CEO of eCaring, a care management software company that exited to a major customer; was CEO of Remtech, a diversified energy and environmental services company; was an officer for strategic planning at JP Morgan Chase; and was CFO at Motionbox.
Robert is currently Managing Partner of Alchemy Value Services. He was Director of New York City's Energy Office, overseeing more than $3 billion in projects. He graduated from Williams College, holds an M.A. in Management from the New School, and is a published author and filmmaker.
Noah is a C-suite operator with more than 25 years leading growth and transformation across iconic consumer and retail brands, including KEH Camera, Levi Strauss, RH and Vineyard Vines. He has delivered over $3 billion in revenue and market-valuation growth, resulting in three highly successful exits in partnership with L. Catterton, Goldman Sachs and Cerberus.
As CEO of KEH Camera he led a profitable, fast-growing platform in the circular economy, scaling the business well ahead of its market. Earlier, as Chief Experience Officer at Vineyard Vines and in senior roles at Levi Strauss and RH, he built consumer brands and operating systems known for disciplined, transformational growth.
At Breaking Wave, Noah focuses on commercial scaling, operator value creation and deal origination.
Rick is a venture strategist, capital advisor and growth architect focused on scaling high-growth businesses and structuring transformative investment opportunities across technology, consumer, entertainment, hospitality and emerging platform sectors. As a Partner at Cypress Ascendant and founder of RBD3 Group, he specialises in venture building, strategic partnerships, capital formation and institutional-grade capital architecture.
He has advised a wide range of growth-stage companies on fundraising, strategic positioning, investor relations, transaction structuring and long-term scaling. As Special Advisor to Events.com, he helped guide the company from a more than 95% pandemic revenue decline to a public listing alongside Bob Diamond and Concord Acquisition Corp II at an approximately $400 million enterprise valuation.
Dash Llewellyn leads the analyst team at Breaking Wave Capital and sets the firm’s technology direction. He runs diligence on live opportunities and built the BWC proprietary AI platform.
Before Breaking Wave he was a software engineer at Klyre Pay, building the copay and reimbursement rails that connect specialty drug manufacturers, providers and pharmacies — and integrating AI into the underlying systems. He studied Computer Science at Rensselaer.
Berkay joined Breaking Wave as an Analyst in May 2026, having spent the prior summer with the firm. He started out somewhere less conventional: professional basketball in Türkiye, which he left at eighteen for finance. He then spent five years at Yıldız Holding, Türkiye’s largest FMCG company, in cash management, working on financial planning and liquidity operations across the group.
Berkay holds an MBA from NYU Stern, where he was a Teaching Fellow for Equity Valuation, and a B.S. in Capital Markets from Marmara University. He is a CFA charterholder and has been investing in public markets since senior year of college.
The desk never closes. Inbound at three in the morning gets the same first look as nine.
From a deck landing in the inbox to a graded, filed, written-up record.
Eight dimensions, hard gates and a written reason under every score — advanced enough that a partner audits the reasoning, not just the verdict.
Investment decisions made by software. It prepares the file; the partnership decides what we buy.
An always-on system running dozens of jobs on timers — it restarts itself and keeps its memory across every deploy.
It works inside the firm's real inbox, data room, calendar and CRM — not a sandbox, not a copy.
One source of truth behind every document and deck, so the firm only ever says one thing at a time.
Output renders straight into our own templates, presentable the moment it exists.
Domain-locked sign-in, role-based permissions and an audit line on every write.
The platform proposes; only a partner commits. Judgment stays human, and senior.
Within 90 days of close we run an aggressive operational reset — vendor renegotiation, procurement, staffing and billing — in the first quarter, not the first year.
Structured BD and sales playbooks from C-suite roles scaling companies from zero to billions.
Unit economics, operating expense rationalisation and procurement leverage inside 18 months.
Split-billing facilitation and revenue-cycle automation convert cycle inefficiency into EBITDA.
The exit buyer is embedded at underwriting, from day one — not discovered at year four.
40+ exits and 4 IPOs across the partners' careers, in healthcare, consumer, media and fintech.
Terms, track record and offering documents are available to verified accredited investors. Nothing on this page is an offer to sell securities.
Pamela and Robert take the first call and every one after it. There is no analyst screen and no relationship manager in between.
Terms, track record and offering documents open once accreditation is verified — handled once, quickly, in confidence.
Introductions are answered the week they arrive. If we are not a fit for your mandate we will say so early rather than keep you warm.
Request the materials, or write to a general partner directly. Nothing on this page is an offer to sell securities.
Accreditation verification, then the data room: PPM, LPA, subscription documents, track record and the model.
Read the day it arrives, every time. Proven concept, consistent customers, a clear path to scale.
Press, co-investors, service providers and anything that does not fit the two boxes to the left.
Research and analysis from the investment team.
Healthcare outran the market as the 10-year yield hit 5.22%. What it means for lower middle market healthcare: the cost of debt, MedPAC's new home health payment study, 340B, and where healthcare capital is being raised.
Why scale is rewarded twice, why the largest consolidators are insurers, and what a durable operating model looks like when an agency sets neither its price nor its volume.
Healthcare was the worst sector on the tape as the curve steepened hard. What it means for lower middle market healthcare: the cost of debt, the 2027 home health rate reset, 340B, and where private deal flow is heading.
Who sets the price, who authorizes the volume, and why the same rate cut is a bad year for one operator and the end for another.
We publish when a piece is done rather than on a schedule. If you want the next one, or want to talk about anything in this one, say hello.
INSIGHTS
In simple terms, a home health agency (HHA) delivers skilled and intermittent clinical care in a patient’s residence: nursing, physical and occupational therapy, speech therapy, medical social work, and aide services. Because the care happens in the home rather than in a facility, it is a capital-light, labor-intensive business: almost no real estate, almost no equipment, and a cost base dominated by clinician wages and travel time.
It is also a narrower business than the surrounding language suggests. Home health is skilled care, ordered by a physician and paid primarily by Medicare. It is not non-medical home care, which assists with daily living, requires no clinical license, and is funded largely by Medicaid and private pay. Nor is it hospice. The three are routinely grouped together as “care at home,” but they have different payers, cost structures, and regulatory exposure.
The consensus case for investing here is demand-side and by now well worn: an aging population, longer life expectancy, and the prospect of technology expanding what can be delivered at home. The demand is real. It is also the least useful part of the analysis, because nobody disputes it and it says nothing about which operators will capture it. The harder questions sit on the other side — how the care is paid for and repriced, who is permitted to deliver it, and who can be hired to do it. All three are pushing this sector toward consolidation.
This piece works through that ecosystem: the regulators who set the price, the insurers displacing them, the scale economics driving consolidation, and our view of what a durable operating model looks like from here. This first part covers the ecosystem, the two payer books, and how payment gets repriced; part two turns to competition, consolidation, and what operators should do about it.
To understand this ecosystem, it helps to separate it into layers — what determines volume, what determines price, what determines cost, and what feeds back into the next period's rate — and then look at how those layers act on each other.
In Exhibit 1, the striking feature is how little of it the agency controls. Volume is authorized elsewhere. Price is set elsewhere. The supply of clinicians is set by a labor market competing with hospitals and retail employers. The only variable the agency owns is what happens between the referral arriving and the visit being delivered. That constraint is narrow, and it is also the entire basis for a durable operating model.
What makes the sector genuinely difficult to navigate is that the same organization can occupy several of these layers at once. A Medicare Advantage (MA) insurer authorizes utilization, negotiates the rate it will pay, and — through Optum at UnitedHealth and CenterWell at Humana — owns agencies that compete directly for the same referrals. No position in that arrangement puts the insurer's interests in the other direction.
Volume: Before a referral becomes revenue, several gates must be cleared. Medicare requires the patient to be homebound and to need intermittent skilled care, certified by a physician following a face-to-face encounter. Hospitals control the discharge flow that generates most referrals. Under Medicare Advantage, the plan adds prior authorization on top. Volume therefore depends not on how many people need care, but on how many can clear all of these at once.
There are two primary sources of patients for home health agencies: traditional Medicare beneficiaries and Medicare Advantage enrollees. The clinical service is broadly the same, but the economics are different.
For traditional Medicare, the agency is paid a case-mix-adjusted amount for each 30-day period of care. That payment does not arrive upfront. Centers for Medicare & Medicaid Services (CMS) phased out split-percentage payments over three years — from 60% of the anticipated amount paid in advance to 20% in 2020, to zero in 2021 — and replaced the Request for Anticipated Payment entirely with a Notice of Admission from January 1, 2022. The notice carries no payment. It must be filed within five calendar days of the start of care, and every day it is late costs the agency one-thirtieth of the period's total reimbursement.
The practical consequence is that the agency admits the patient, files a no-pay notice, funds thirty days of clinician wages and mileage out of its own balance sheet, and then bills. It finances the episode itself. Working capital therefore constrains how fast an agency can grow, and larger operators carry it more easily than smaller ones.
The margins on traditional Medicare beneficiaries are attractive, but stratified by size:
| Volume Quintile | FFS Medicare Margin, 2024 | Share of agencies | Share of 30-day periods |
|---|---|---|---|
| First (smallest) | 14.4% | 20% | 3% |
| Second | 15.1% | 20% | 7% |
| Third | 17.6% | 20% | 11% |
| Fourth | 20.3% | 20% | 19% |
| Fifth (largest) | 23.2% | 20% | 60% |
The margin ladder rises with scale, which the Medicare Payment Advisory Commission (MedPAC) attributes to the economies available to larger operations. These are Medicare margins, which measure Medicare revenue against the costs Medicare allows — the profitability of one payer's book. The same freestanding agencies earned an all-payer margin of 5.0% in 2024. The gap between 21.2% on fee-for-service Medicare and 5.0% across everything is the single most important number in this sector, because it says the attractive margin belongs to one payer and everything else is roughly breakeven.
For Medicare Advantage patients, the agency negotiates directly with the plan, and payment typically comes per visit rather than as a lump sum for the period. The volume of care differs too: after adjusting for patient characteristics, MA enrollees received 18.2 home health visits against 20.4 for fee-for-service beneficiaries, and 1.8 fewer visits even within the same agency. Operators are explicit about the economics — one large chain told MedPAC that MA payment frequently fell below the cost of providing care, and that all else equal, they preferred admitting fee-for-service patients.
| Category | Medicare Advantage | Fee-for-service |
|---|---|---|
| All users | 18.2 | 20.4 |
| No prior hospital stay | 17.4 | 19.7 |
| Prior hospital stay | 19.2 | 21.2 |
Traditional Medicare is plainly the better pool. But an agency cannot simply choose it because the payer and the referral channel are entangled. The same hospital discharge relationships that supply fee-for-service admissions also send MA patients, and agencies that decline the unprofitable ones risk losing the profitable ones. Operators told MedPAC they continue admitting post-hospital MA patients despite the payment levels precisely to maintain those hospital relationships. Payer mix is therefore not a variable an agency optimizes freely; it is largely inherited from its referral base, and it drifts with the enrollment mix of the surrounding population.
The consequence shows in the mix. The number of Medicare beneficiaries receiving home health care has not grown — it has hovered near five million over the last seven years — while the payer behind that volume has shifted decisively toward MA. MA rose from 30% of eligible beneficiaries in 2013 to 55% in 2025. In 2021, the last year with published data, MA already accounted for about 45% of home health users in MedPAC’s analysis, and on our estimates, the two payers reach roughly parity by 2025 — the crossing point in Exhibit 4.
For an operator, this implies that the demographic wave has not produced volume growth in home health. What it has produced is a substitution: the profitable pool is shrinking at roughly the rate the unprofitable one expands. Growth therefore has to come from taking share from competitors and successfully scaling up.
Referring back to the ecosystem diagram, several actors determine what an agency is paid for the same service. What makes this difficult to project is that the payment system observes operator behavior and adjusts accordingly. Efficiency gains visible to the payment formula are recaptured on a published schedule. Efficiency gains invisible to it are not recaptured on that same schedule — and because rates are set on industry aggregates, an operator that improves faster than its peers keeps the difference. The mistake you can make as an investor is treating all operating improvement as equivalent.
Exhibit 6 shows, in simplified form, how the payment rate is set for traditional Medicare (FFS) beneficiaries.
CMS is the federal agency within the Department of Health and Human Services. It administers Medicare, co-administers Medicaid with the states, and runs the Affordable Care Act (ACA) marketplaces. CMS can only act within the authority Congress grants it — but within that authority, it adjusts the base rate every year through rulemaking, with no further legislation required. Rulemaking involves a proposed rule, a public comment period, and then a final rule carrying the force of law, which is why the numbers are contestable: for 2026, CMS proposed a permanent adjustment of 4.059% and finalized 1.023% after comment.
In the Bipartisan Budget Act of 2018, Congress required that the new payment model be budget-neutral to the old model and directed CMS to correct any divergence between assumed and actual spending. As an example, the bridge graph below in Exhibit 7 illustrates the adjustments applied to the 2025 base rate to arrive at the 2026 base payment rate.
The remaining piece in that mechanism is MedPAC which sits first in the rate-setting diagram above. MedPAC is an independent body that analyzes payment adequacy and reports to Congress each March. It has no authority to set rates; it provides inputs for Congress to make decisions. For context, MedPAC has recommended a 7% cut to the base payment rate in each of the last three cycles, pointing to fee-for-service margins for freestanding agencies averaging 21.2% in 2024 and reaching 23.2% among the highest-volume agencies. The Commission's position is that excess payment dulls the incentive to deliver care efficiently; the industry's counterargument is that this margin is computed on a payer now covering less than half the market and says little about whether an agency is viable overall. The useful way to read MedPAC is as a persistent downward bias in the rate environment rather than a schedule of cuts, so operators should think about how to position themselves going forward to mitigate the effects of downward rate adjustments.
The behavioral adjustment is an arithmetic comparison between what Medicare actually spent and what it would have spent had operators behaved as CMS assumed in 2019. Those assumptions were specific: agencies would code the highest-paying available diagnosis as the principal one, capture additional comorbidities on the claim, and, when a period fell one or two visits short of the LUPA threshold, add the visits to secure a full payment. CMS also reserved the right to count behavior changes it had not predicted.
What unites everything in that list is that each of them changes what Medicare pays. The behavioral adjustment is computed from claims and assessment data — the diagnosis coded, the case-mix group assigned, the visits billed. It contains no information about what those visits cost HHAs to deliver.
This produces two categories of operating improvement that behave in opposite ways.
| Visible to the payment formula | Invisible to it |
|---|---|
| Principal diagnosis selection | Cost per visit |
| Comorbidity capture on claims | Clinician utilization and route density |
| Visits relative to LUPA threshold | Travel time between homes |
| Case-mix group assignment | Documentation time per visit |
| Episodes per patient | Turnover and early-tenure attrition |
| Denial rates and days to collect | |
| Overhead per episode |
Anything that improves the left column raises Medicare’s spending, which is precisely the quantity CMS measures and corrects. On the other hand, changes in the right column do not necessarily affect Medicare’s spending, so the entire productivity gain there can land in the provider’s margin.
Those gains are not guaranteed to stay in the margin because of a second, slower channel. Cost data reaches the rate-setting process through agency cost reports, which is how MedPAC computes the margins it reports each March. Cost-side efficiency is observed — just slowly, in aggregate, and only as a recommendation that Congress may or may not act on. In the left column, the recapture is mechanical and requires no vote. In the right column it is discretionary and industry-wide.
Medicare pays a national rate. An agency’s margin is that rate minus its cost, so it depends on where its cost sits relative to the industry’s.
If the entire industry lowers its cost per visit, margins rise across the board; MedPAC observes the higher margins, and downward pressure on the rate follows. Industry-wide efficiency is competed away into the rate.
Rates are set on aggregates, but a single operator is not an aggregate. An agency that takes cost out faster than its peers keeps the difference for as long as the gap persists. The same logic runs through quality: home health value-based purchasing adjusts payment by up to five percentage points based on performance measured against peers, so quality is also scored relatively.
This is why a rate cut does not compress operators equally. Apply a mechanical 7% cut to the base rate, holding costs constant, and the smallest agencies’ Medicare margins fall from 14.4% to about 8%, while the largest fall from 23.2% to about 17%. The same cut can be an existential event for one group and a bad year for the other.
On the MA side, there is no equivalent formula. An agency negotiates directly with each plan, and the terms reflect relative bargaining power rather than a cost-based calculation. In practice, that means three things work differently.
The unit of payment changes. MedPAC reports that plans may pay for a different unit of service than fee-for-service Medicare does — per visit for home health. Under the 30-day period, every visit is a cost against a fixed payment. Under per-visit terms, every visit is revenue. An agency serving both books runs opposite incentives through the same schedulers and clinicians.
The plan controls volume as well as price. Nearly all plans require prior authorization for home health, typically approving a set number of visits with further authorization needed beyond that. Operators told MedPAC these were difficult to obtain even when a clinician had assessed the need. The result is the visit gap shown earlier: fewer visits per MA patient, even within the same agency.
The agency has no structural leverage against plans. MA plans must demonstrate network adequacy across 29 clinician specialties and 14 facility types in every county they serve, but those requirements do not apply to home health agencies. MedPAC states that the absence of network adequacy standards may give plans greater negotiating leverage, particularly where they can substitute another provider.
Medicare accounts for roughly 90% of home health volume (MedPAC, June 2026), so an agency depends almost entirely on one program — yet it has little leverage over the fastest-growing part of that program. That weak position contributes to the gap between an all-payer margin of about 5% and a fee-for-service Medicare margin of around 20%.
It would be natural to expect agencies’ margins to fall as MA penetration rises. MedPAC tested exactly that and found no statistically significant association between market-level MA penetration and home health agencies’ all-payer margins. Its own explanation is that MA has grown steadily for years, and most agency costs are variable; providers may have responded by reducing staffing or other costs, holding margins in place. The Commission also found differences by provider size. Read that way, the aggregate did not move because operators absorbed the pressure — and the operators able to absorb it are the ones that survive.
The fee-for-service mechanism reprices on a published schedule that an operator can read. The MA mechanism reprices continuously, at contract renewal, through a counterparty with no obligation to contract at all.
Every point of MA penetration moves a share of an agency's volume from the FFS book to the negotiated one.
Part two looks at what that does to the competitive field — why scale is rewarded twice, why the largest consolidators are insurers, and what a durable operating model looks like from here.
MedPAC, Report to the Congress: Medicare Payment Policy, March 2026, Chapter 8.
MedPAC, Report to the Congress: Medicare and the Health Care Delivery System, June 2025, Chapter 3.
MedPAC, Report to the Congress: Medicare and the Health Care Delivery System, June 2026, Chapter 4.
CMS, Home Health Prospective Payment System: CY2019 Final Rule; CY2026 Final Rule (CMS-1828-F); CY2027 Proposed Rule (CMS-1844-P).
INSIGHTS
Part one worked through how a home health agency earns a dollar and how Medicare takes some of it back. Two conclusions carry forward. The payment formula recaptures efficiency it can observe — coding, case mix, visit counts — but not efficiency it cannot, such as cost per visit, administrative burden, or working capital. And because rates are set on industry aggregates, what matters is not how efficient an operator is in absolute terms but how efficient it is relative to everyone else. Two exhibits from part one are repeated below, since the argument here rests on them.
Scale is becoming the dividing line in this sector. As Exhibit 2 shows, fee-for-service Medicare margins rise steadily with volume — from 14.4% in the smallest quintile to 23.2% in the largest, a gap of 8.8 percentage points. Put differently, the largest agencies earn roughly 60% more margin on each Medicare dollar than the smallest. The Medicare Payment Advisory Commission (MedPAC) attributes the difference to the economies of scale available to larger operations.
| Volume Quintile | FFS Medicare Margin, 2024 | Share of agencies | Share of 30-day periods |
|---|---|---|---|
| First (smallest) | 14.4% | 20% | 3% |
| Second | 15.1% | 20% | 7% |
| Third | 17.6% | 20% | 11% |
| Fourth | 20.3% | 20% | 19% |
| Fifth (largest) | 23.2% | 20% | 60% |
The M&A market prices the same thing. FOCUS Investment Banking's 2026 benchmarks put small, single-branch skilled agencies at roughly 3–6x EBITDA, regional multi-branch operators at 6–9x, and scaled multi-state platforms at 9–12x or higher. Kinderhook's take-private of Enhabit, at roughly 10.2x adjusted EBITDA, anchors the upper tier.
| Tier | Earnings basis | Indicative multiple |
|---|---|---|
| Small, single-branch, owner-operated | EBITDA | 3–6x |
| Regional multi-branch | Adjusted EBITDA | 6–9x |
| Scaled multi-state platform | Adjusted EBITDA | 9–12x |
| Anchor: Enhabit take-private, 2026 | Adjusted EBITDA | 10.2x |
The two tables measure different units — MedPAC's quintiles are individual agencies, while multiples are paid for whole enterprises that may own locations across every quintile — so they don't line up row by row. However, the direction is clear. A larger operator earns better unit economics at its locations, and the market then pays more for each dollar of those earnings. Scale is rewarded twice. What follows is the consolidation trend we have seen in the market, and it explains why the deal market has shifted from forming new platforms to adding onto existing ones. In the fourth quarter of 2025, Mertz Taggart recorded just three home health transactions — all add-ons by sponsor-backed portfolio companies.
The largest consolidators in home health are insurers.
| Insurer | Platform | Transaction | Footprint |
|---|---|---|---|
| UnitedHealth (Optum) | LHC Group | Closed 2023, ~$5.4B | Combined with Amedisys: ~10% of U.S. home health |
| UnitedHealth (Optum) | Amedisys | Closed August 2025, $3.3B; 164 sites divested | |
| Humana | Kindred at Home → CenterWell Home Health | 2021, $8.2B enterprise value for 100% (acquired remaining 60%) | 350+ locations, 38 states (2022) |
For an insurer, home health is a cost-management tool: it is far cheaper than a skilled nursing stay, and MedPAC's data shows MA plans use more home health after a hospitalization than fee-for-service plans do. By owning the platform, UnitedHealth and Humana capture the savings internally, rather than paying a third party for it. For example, one rationale for Humana’s acquisition of Kindred was the footprint and its match with Humana’s MA members. Kindred at Home was the nation's largest home health and hospice provider at the time, and its footprint overlapped by about 65% with Humana’s individual Medicare Advantage membership.
This returns us to the observation from the ecosystem diagram in Exhibit 1. A vertically integrated insurer authorizes utilization, negotiates the rate paid for it, and owns agencies that compete for the same referrals. In each role, its interest points in the same direction.
To be fair, these platforms describe themselves as payer-agnostic and serve patients across payers, including members of other insurers and fee-for-service beneficiaries. There is limited public evidence on steering in home health specifically, and this piece does not claim it occurs. The point is structural rather than behavioral: an independent operator negotiating with an integrated insurer faces a counterparty that sees both the payment data and the competing provider's economics, and that owes the operator nothing.
Volume: A payer-owned platform can draw on its parent's member flow while an independent operator cannot. Its volume must come from the channel it can earn — hospital and physician preference — which is why the referral relationship sits at the center of any durable model.
Exit: Insurers have been the premium strategic buyers in this sector, but the Amedisys transaction took roughly two years from announcement to close, drew a federal antitrust suit, and required what regulators called the largest divestiture of outpatient sites ever used to settle a merger challenge. The next large insurer acquisition will face at least that scrutiny. A sponsor underwriting a platform today should not assume an insurer takes it out at the end.
Supply: The same scrutiny creates acquisition opportunities for mid-sized consolidators. Regulators wanted the divested Amedisys and Optum locations placed with operators able to compete independently, and they went to BrightSpring, which took 115 sites, and Pennant, which took 49.
Independent operators cannot match an insurer's member flow or its information advantage. What it can do is be better at the things inside its own business. That is where the operating model comes in.
Return once more to the ecosystem diagram in Exhibit 1. The agency sets neither its price nor its volume, and it does not control the labor market it hires from. Everything durable has to be built inside the one box it does control. And given how this payment system works, each piece has to pass three tests: it must be invisible to the payment formula, it must improve the operator's position relative to peers rather than just in absolute terms, and it must protect the referral channel that supplies the volume.
Cost per visit, measured against peers. The rate is set on industry aggregates, so the only margin that survives repricing is the gap between your cost structure and everyone else's. That makes the relevant benchmark not last year's performance but the industry median — clinician visits per day, route density, travel time between homes, and overhead per episode. None of these appear on a claim, and they all compound. An operator improving them faster than the industry keeps the difference for as long as the gap persists.
Administrative burden, where technology actually belongs. The strongest case for AI in home health is administrative: documentation and assessment time, scheduling, eligibility checks, and above all authorization. MA plans process roughly 1.7 prior authorization requests per enrollee across all services, against 0.02 in fee-for-service (KFF analysis, as cited by MedPAC, June 2026). For a home health agency, each authorization and reauthorization is labor that no payer reimburses. The evidence base is still early — most quantified claims for newer tools come from vendors, and telehealth or remote monitoring appeared in just 2.2% of 30-day periods in 2024 — but administrative cost sits squarely on the side of the ledger the payment formula cannot see.
Working capital as a growth constraint. Since 2022, an agency receives nothing when it admits a patient. It files a notice of admission within five days — each day late forfeits a thirtieth of the period's payment — funds a month of wages and mileage, and then bills. Every day of billing lag and every denied claim is capital the agency has already spent. For a small operator, this caps how fast it can grow; for a disciplined one, a short cash cycle is what funds acquisitions. It is also one of the less visible reasons scale compounds.
Early-tenure retention. In a labor-constrained business, attrition concentrates in the first months of employment, when replacement cost is highest and onboarding, scheduling stability, and caseload design matter most. Retention is a cost-per-visit lever in disguise: every clinician lost early is a recruiting cost, a training cost, and a period of lower productivity for whoever covers the caseload.
The hospital relationship, and the payer mix it brings. Payer mix is inherited from the referral base. The same discharge planners who send fee-for-service patients also send MA patients, and an agency that declines the unprofitable ones risks losing the profitable ones — which is why operators told MedPAC they keep admitting MA patients to protect hospital relationships. The better strategy is to become the agency hospitals prefer to discharge to. That preference is earned with fast starts of care, available capacity, clinical capability, and low readmissions — and increasingly with authorization speed: MA patients discharged to home health have been found to have hospital stays about 8% longer than comparable fee-for-service patients (MedPAC, June 2026), consistent with post-acute authorization delays. An operator that clears authorization quickly frees a hospital bed. In a shrinking fee-for-service pool where growth means taking share, referral preference is a durable source of volume.
Coding accuracy, not case-mix optimization. Diagnosis coding and comorbidity capture are exactly what the behavioral adjustment measures. Chasing them is borrowing against next year's rate, and it draws audit scrutiny. Complete and accurate documentation still matters — it protects revenue the agency is entitled to and holds up under review. The version of case mix that is genuinely defensible is clinical capability: the ability to serve complex patients well, which shows up in quality scores and hospital preference rather than in coding.
These are not separate initiatives. Lower cost per visit protects margin through rate cuts, and the protected margin funds acquisitions. Administrative efficiency lowers cost and speeds authorization, which earns hospital preference. Hospital preference delivers share in a pool that is not growing. A short cash cycle lets the operator grow faster than working capital would otherwise allow. And scale then feeds back into every one of them — better unit economics at each location and a higher multiple on the combined earnings.
The model that fails looks for margin in the wrong places: coding intensity and visit reduction, which the payer can see, or the staffing extraction documented in research on private equity in post-acute care (Gupta et al., Review of Financial Studies, 2024). The first two are repriced. The third is the most damaging to patients and, in a business where labor is the binding constraint, the least profitable.
None of this describes a rising tide. Rate pressure in home health sorts the sector rather than shrink it. Lower rates are a win for taxpayers and the Medicare trust funds, which is what MedPAC’s recommendations are designed to deliver. They are a win for operators whose cost position sits ahead of the industry, who absorb the cut, keep a defensible margin, and acquire the agencies that cannot. And they are an exit for operators behind the industry, for whom the same cut turns a thin margin into none.
The demographic argument tells you how many people will need care. It does not tell you who will be paid to deliver it, or at what margin. The margin ladder, the multiple ladder, and the gap between what the payment formula sees and what it does not — those do.
MedPAC, Report to the Congress: Medicare Payment Policy, March 2026, Chapter 8.
MedPAC, Report to the Congress: Medicare and the Health Care Delivery System, June 2025, Chapter 3.
MedPAC, Report to the Congress: Medicare and the Health Care Delivery System, June 2026, Chapter 4.
CMS, Home Health Prospective Payment System: CY2019 Final Rule; CY2026 Final Rule (CMS-1828-F); CY2027 Proposed Rule (CMS-1844-P).
FOCUS Investment Banking, Home Health and Hospice EBITDA Multiples: 2026 Report.
Mertz Taggart, Home-Based Care M&A Reports, Q4 2025 through Q2 2026.
PitchBook, Q1 2026 Healthcare Services Report.
Enhabit, Inc., FY2025 Form 8-K; Enhabit and Kinderhook Industries transaction announcement, February 2026.
U.S. Department of Justice, United States et al. v. UnitedHealth Group Inc. and Amedisys, Inc., Proposed Final Judgment and Competitive Impact Statement, August 2025.
Humana Inc., Form 10-K for fiscal year 2022.
KFF, analysis of Medicare Advantage prior authorization requests, as cited in MedPAC, June 2026.
Gupta, Howell, Yannelis, Gupta and Matvos, “Owner Incentives and Performance in Healthcare: Private Equity Investment in Nursing Homes,” Review of Financial Studies 37(4), 2024.
WEEKLY MEMO · WEEK OF SEPTEMBER 28, 2026
PAST / PRESENT The week ending October 1, 2026 delivered a clean bifurcation: the Nasdaq 100 (QQQ) was the only major index to post a gain, up +0.68%, while everything else softened — the S&P 500 (SPY) shed −0.22%, the Dow (DIA) dropped −1.23%, and the Russell 2000 (IWM) gave back −0.16% [38][39][44]. The session that mattered was Thursday's employment print [1], which showed unemployment ticking higher and job growth slowing; that single data point collapsed the front end, with the 2Y Treasury falling 9bp to 4.78%, while simultaneously confirming that growth is wobbling enough to keep the Fed on hold in October [47][50] — a rare simultaneous dovish-front/hawkish-long dynamic that drove the 10Y up 6bp to 5.24% and the 30Y up a remarkable 14bp to 5.61% [5][58]. The steepening of 2s10s to +46bp is a regime signal: the market is pricing fiscal deterioration and term-premium normalization, not imminent cuts. The week's single most important sector print was XLV, which collapsed −2.65% [38][45] — worst sector on the board by a country mile — driven by Medicare Advantage reimbursement anxiety, site-neutral payment overhang, and the approaching CY2027 PDGM rate reset [186][190][191]. Earnings season for Q3 opens imminently [62][64], with healthcare names under particular scrutiny. AHEAD Q3 earnings releases will stress-test MA plan margins against the V28 risk-score phase-in and the September Fed hike [54][56]; any guidance cut from a large MA plan triggers another leg down in XLV and sets the narrative for the LMM valuation conversation. Watch the 10Y: a break above 5.35% would reprice leveraged buyout underwriting across the board.
| INDEX | LEVEL | WK |
|---|---|---|
| S&P 500 (SPY) | 769.64 | -0.22% |
| Dow Jones (DIA) | 511.10 | -1.23% |
| Nasdaq 100 (QQQ) | 749.58 | +0.68% |
| Russell 2000 (IWM) | 281.52 | -0.16% |
| S&P Health Care (XLV) | 166.18 | -2.65% |
Sector leadership: Technology (QQQ +0.68%) led on continued AI infrastructure spending — Google's $920M AI pact [6] is one data point in a broader capex cycle — while healthcare (XLV −2.65%), basic materials, and international indices bore the week's losses [38][45]. The divergence between tech-growth optimism and healthcare policy pessimism is the defining cross-sector trade heading into Q4.
| INDEX | LEVEL | WK |
|---|---|---|
| Korea (EWY) | 191.88 | +2.51% |
| China (FXI) | 33.19 | -2.27% |
| Japan (EWJ) | 98.92 | +1.01% |
| Europe (VGK) | 86.38 | -2.54% |
| Germany (EWG) | 41.30 | -2.27% |
| UK (EWU) | 46.18 | -2.41% |
| ASSET | LEVEL | WK |
|---|---|---|
| WTI crude | 96.16 | -0.26% |
| Brent crude | 113.96 | -0.81% |
| Natural gas (UNG) | 10.47 | -5.93% |
| Gold (GLD) | 380.14 | -3.37% |
| Silver (SLV) | 54.74 | -5.85% |
| Copper (CPER) | 39.52 | -2.68% |
| Platinum (PPLT) | 15.43 | -4.10% |
| Wheat (WEAT) | 24.75 | -2.94% |
| Corn (CORN) | 18.85 | -4.46% |
| DXY (UUP) | 28.89 | +0.94% |
| EUR/USD | 1.1225 | -1.56% |
| USD/JPY | 157.67 | +0.05% |
| Bitcoin | 85,297.57 | +1.04% |
The dollar (DXY/UUP) strengthened +0.94% on the week, with EUR/USD dropping −1.56% to 1.1225, pressuring European exit valuations for any cross-border secondary process [25][96]. That dollar strength came despite the softer jobs print [1], which tells you it is being driven by safe-haven flows out of a deteriorating European tape — VGK fell −2.54%, EWG −2.27%, EWU −2.41% — rather than pure Fed hawkishness [30][33]. The Asian picture is split: EWY (Korea) was the lone bright spot at +2.51% even as fundamental chip-sector data remains weak [139][143][146], while FXI (China) fell −2.27% as Beijing closed hundreds of smaller banks in a financial-system consolidation move [18]. Crude's behavior is the most important commodity signal for the cost-of-capital path: WTI at $96.16 (−0.26%) and Brent at $113.96 (−0.81%) are elevated but not spiking despite active Middle East conflict [21][22][129][130], as Gulf crude flows have nearly recovered to pre-war levels [134][135][137]. Gold's −3.37% decline and silver's −5.85% drop alongside a stronger dollar represent a risk-off-to-dollar rotation rather than disinflation, consistent with the long-end yield surge. For family-office and non-US investors tracking this letter: dollar strength compresses the NAV of non-US portfolios in USD-denominated terms and can introduce timing friction in allocation decisions from European and Asian LPs.
THE WEEK'S FLASHPOINTS
HEADLINE RISK Trump's "very soon" Iran peace statement [35] is the cleanest example this cycle of policy-by-announcement whipsaw: the statement moved sentiment in oil pits intraday but did not hold because no implementation mechanism accompanied it — no negotiated framework, no ceasefire structure, no IAEA timeline. Brent's −0.81% weekly move is as much about the Hormuz supply recovery [137] as about any peace signal. The analytic discipline here is strict: headline-driven oil moves that lack a signed implementation artifact mean-revert within 48–72 hours; implemented policy — like the actual rerouting of Gulf crude with US Navy escort — does not. LBO underwriting should reflect the $96–114 WTI/Brent range as a durable floor, not a "Trump peace dividend" scenario that may never clear.
READ-THROUGH FOR HEALTHCARE LMM The direct healthcare LMM linkage to geopolitics is narrower than macro commentary typically asserts, and it is worth saying so plainly rather than manufacturing a connection. The real channels are: (1) API and generic drug ingredient sourcing, where the US-China tariff truce [151] provides temporary relief to companies carrying China-sourced pharmaceutical inputs, but the 30-day timeline on tariff implementation credibility [157] means procurement teams should not yet renegotiate long-term contracts; (2) the oil and inflation path feeding the rate at which capital is borrowed — WTI at $96+ sustains headline CPI stubbornness, which gives the Fed political cover to hold at 3.75–4.00% [54] and keeps the long end elevated, directly raising blended cost of debt; and (3) the Ethiopia conflict [23] and Houthi-Aramco dynamics [21] have no material direct read-through to LMM home health, 340B infrastructure, or RCM automation assets — we note them for completeness and flag the situations as ones to monitor at the macro level.
| METRIC | READING | READ-THROUGH |
|---|---|---|
| Healthcare PE deal value '25 | Record $191B disclosed [106][217] | Validates category; megafund capital inflating large-deal multiples, not LMM |
| Concentration (Q1 2026) | Physician groups = 46% of deal volume [80] | Structural demand for physician-adjacent plays; confirms home health / care-coordination thesis lanes |
| LMM healthcare multiples | $500K–$10M EBITDA assets: historically high [108]; LMM buyout funds raised ~$59B since 2022, +40% vs. prior 3-yr period [109] | Entry discipline critical; sub-8x EBITDA on platform builds; add-ons at 4–6x are the right target range |
| LMM deal flow (Axial) | VERTESS ranked #1 sell-side advisor by Axial for 2026 [103][105]; new healthcare transactions via Axial up 60% in comparable prior period [107] | Axial channel is deepening; VERTESS relationship worth cultivating for proprietary sourcing |
| US IPO exits '25/'26 | IPO postponements accelerating in Q3 2026 [65]; Oura pulled Nasdaq filing amid market uncertainty [66][67][68][69] | Exit via IPO effectively closed for the current hold period; strategic M&A or secondary PE is the underwrite |
| Family-office appetite | Citi 2026 Global Family Office Report: shifting toward public equities; liquidity concerns rising [112][115]; Goldman: ~40% of FOs plan to raise PE allocations [116] | Mixed signal — headline shift to public equities reflects valuation discipline, not PE aversion; family offices with established alts programs are the natural audience |
| Dry powder / secondaries | Mid-market healthcare funds raised ~$59B since 2022 [109]; secondary market liquidity gap remains a structuring consideration [114] | Co-investment demand rising (88% of LPs intend up to 20% co-invest by 2030 [89]); co-invest sleeve structures capture family-office appetite effectively |
The private market barbell has sharpened: megafunds ($5B+) are chasing AI-enabled physician roll-ups and large platform deals that drove the $191B record [106][82], while LMM specialists are operating in a sub-$100M deal-value band where proprietary sourcing and operational expertise — not financial engineering — generate alpha. McGuireWoods' 19th Annual HealthcareGO Conference (October 2, 2026) highlighted compliance and scarcity as the defining themes for home-based care dealmaking [102][177], which maps precisely onto Breaking Wave Capital's thesis lanes. A newly launched healthcare-focused PE firm, Haelan Capital, entered the market this week with its first investment [215], signaling that the LMM healthcare GP formation cycle is active — competition for quality assets is real.
THE BWC THESIS IN PLAIN LANGUAGE Breaking Wave Capital targets healthcare lower middle market assets — specifically home-health consolidation platforms, 340B program infrastructure, and RCM automation companies — in the $3–15M EBITDA range where megafund capital is structurally unable to operate efficiently. The record PE deal value in 2025 [106][217] is a market validation, not a deployment signal at our scale: that capital concentrated in the top quartile of deal size. The actual opportunity sits in the scarcity dynamic that McGuireWoods and Axial are both flagging [102][103][107] — compliance-driven consolidation in home health, 340B contract-pharmacy complexity creating picks-and-shovels demand, and RCM automation displacing manual billing operations in sub-$50M revenue companies that cannot attract megafund attention. The IPO exit closure [65][66][68] is the one portfolio construction reality to communicate clearly: hold periods are 5–7 years minimum, exits are strategic M&A or secondary PE, and that is a feature — lower volatility, no public-market lock-up cliff — not a bug for the family-office investor base.
The headline mechanics. CMS published the CY2027 Home Health PPS proposed rule in July 2026 [190][191], with a final rule expected by November. The proposed update carries a net aggregate payment increase of approximately +0.5% — but that headline number masks the behavioral-adjustment recalibration that is the actual valuation-relevant figure. CMS is recalibrating the permanent behavioral adjustment applied under PDGM to account for coding intensity and clinical grouping shifts since the 2020 implementation [191][193]. The CY2026 final rule [193] already embedded a permanent adjustment of −2.890% to address PDGM-era coding behavior, layered on top of prior-year adjustments. Operators who built revenue models on pre-adjustment PDGM episode rates are now facing a compounding downward recalibration cycle that is not visible in the headline "+0.5%" figure.
The PDGM behavioral-adjustment machinery. PDGM's 30-day payment unit structure creates a systematic incentive to front-load clinical visits in each episode, which CMS scores as behavioral — i.e., coding that responds to payment structure rather than clinical need. Each annual rulemaking cycle allows CMS to apply a retrospective behavioral adjustment using the most recent claims data, meaning operators never fully "bank" a favorable coding pattern. The proposed CY2027 rule continues this recalibration logic [190][191]. For acquirers: a target company showing EBITDA margin expansion since 2022 must be stress-tested for whether that expansion is PDGM-coding-driven (and therefore impermanent) or genuine scale and mix improvement (and therefore acquirable).
Second-order effects.
Any engagement in this lane requires a line-by-line PDGM cohort analysis of the target's clinical groupings over the last four quarters, with a specific look at LUPA (Low Utilization Payment Adjustment) rate trends as a proxy for visit-pattern gaming. The CY2027 proposed rule [190][191] is the live regulatory document; management fluency with the behavioral-adjustment mechanics is itself a diligence signal. Targets where more than 60% of episodes fall in early/acute PDGM clinical groupings carry recalibration-risk concentration that must be priced into entry.
Contract-pharmacy restrictions. The legal landscape shifted materially in February 2026 when a federal appeals court upheld Louisiana's 340B contract-pharmacy protection law [174], following a pattern of state-level legislative action now spanning at least 36 manufacturers that have imposed restrictions [173]. AbbVie, PhRMA, and AstraZeneca challenged the Louisiana law as unconstitutional; the appellate court rejected that challenge [174], giving state 340B protection statutes a constitutional green light that will likely accelerate similar legislation in other states. The National Law Review's September 28 summary [169] confirms that litigation activity remains active across multiple jurisdictions this week. Both sides of the policy debate — covered entities and manufacturers — are now converging on two specific structural reforms: a data clearinghouse for contract-pharmacy claims and a clearer statutory definition of "patient" for 340B eligibility purposes [168]. That convergence is significant: it signals that the 340B fight is shifting from binary restriction/access disputes toward a data-governance regime — which is precisely where picks-and-shovels vendors operate.
The Rebate Model Pilot. HRSA's ongoing conversation about a manufacturer-proposed rebate model (replacing upfront discounts with post-sale rebates) remains unresolved at the statutory level. The JD Supra analysis from September 28 [170] emphasizes that academic medical centers and large health systems — the covered entities most exposed — have the most to lose if a rebate model erodes their ability to generate 340B revenue across contract-pharmacy networks. For LMM 340B-adjacent pharmacy operators: the rebate model, if implemented, would require real-time claims reconciliation infrastructure that most sub-scale operators lack. That creates a compliance-driven consolidation dynamic where technology-enabled operators with HRSA audit-ready data systems command premium multiples.
Market read. The 340B compliance infrastructure market is the picks-and-shovels play. The convergence on a data clearinghouse [168] validates the vendor category: companies building HRSA-audit-ready claims data platforms, contract-pharmacy TPA (third-party administrator) services, and manufacturer-side dispute-resolution tools are structurally well-positioned regardless of which side wins the policy argument. Named vendors active in this space include Verity Solutions and Sentry Data Systems (340B compliance platforms).
RCM adoption reality. Capstone Partners reported a 93.8% surge in AI-enabled healthcare IT M&A in 2026 [196] — a headline that sounds like universal adoption but contains a contradiction: if AI is penetrating RCM at that deal velocity, why are most sub-$50M revenue medical groups still running denial management on spreadsheets? The answer is a deployment gap between platform-level vendors (who are being acquired) and point-solution vendors (who are still selling to the same overburdened billing managers). The VERTESS/Axial ranking [103][199] and the Scoperesearch RCM valuation analysis [200] both confirm that R1 RCM has been the largest acquirer by deal volume and dollars since 2019, absorbing capacity that should theoretically be democratizing AI-enabled billing. It is not democratizing — it is consolidating into a three-to-four vendor oligopoly at the large-hospital end, leaving the LMM RCM market structurally fragmented and acquisition-ripe.
Funding & the two-tier market. Crunchbase data shows an estimated $10.7B into AI-powered health tech through 2025 [213], with AI pulling in roughly half of all US VC in the most recent quarter [97]. The tier-one end of that market is now at venture-scale valuations that have no LMM relevance: Assort Health hit $1.2B valuation in three years [208], Heidi doubled to $900M [207], and the top AI healthcare startups (Tempus AI at $14B, Abridge at $5.3B, Nabla at $5.3B [211]) are competing for institutional crossover capital. Pearl Health raised $110M in debt and equity to build out its AI platform for primary care [209]. The tier-two market — sub-$50M valuation, pre-Series B, specific workflow automation (prior authorization, denial management, coding audit) — is where Breaking Wave's RCM thesis lane operates. Arintra (AI-powered prior authorization) and Happy Health received funding in the October 1 tracker [204], consistent with this subsegment's continued deal activity.
Moats vs. commoditization. The durable-moat companies in this cycle are those with data network effects that cannot be replicated by a GPT wrapper: Tempus AI's clinical-genomic data corpus [211], Abridge's ambient documentation trained on physician-patient encounter audio at scale, and R1 RCM's payer-contract database depth [200]. Each of these has an asset — proprietary training data, multi-year payer relationships, genomic annotations — that a new entrant cannot replicate by fine-tuning a foundation model. The commodity tier is everything built on top of OpenAI's API for generic prior-auth letter generation, clinical documentation summarization without specialty-specific training, or generic coding audit flagging without payer-specific denial-pattern data. The OpenAI safety leadership resignation [12] — the company's culture described as "broken" by a departing safety leader — is a governance risk signal relevant to any portfolio company that has made OpenAI API dependency central to its product. Vendor concentration risk on a single foundation model provider with governance uncertainty is a diligence flag, not a dealbreaker, but it belongs in any investment committee analysis.
Medicare Advantage & VBC. The September Fed hike to 3.75–4.00% [54][56] lands on MA plans already under pressure from the V28 risk-score phase-in — CMS's multi-year recalibration of MA risk adjustment that is reducing benchmark payments for high-acuity coding that grew faster than actual population health trends. The phase-in, which runs through 2026, is compressing plan margins precisely as rates are rising, making the equity math for large MA operators (Humana, CVS/Aetna, Centene) extremely difficult — which is why XLV fell 2.65% this week [38][45]. MGMA's September 28 analysis [189] outlined a 2027 physician fee schedule pay cut, the end of MIPS, and additional federal changes — a compounding reimbursement headwind for the physician-group and VBC-enabler subsegment. Named VBC enablers — Privia Health, Agilon Health, Oak Street Health (now part of CVS) — face benchmark deterioration as MA plan retrenchment reduces the capitation pools available for risk arrangements. Pearl Health's $110M raise [209] is a counter-signal: primary-care VBC infrastructure is still attracting capital even as large-plan margins compress, because the thesis is that well-run risk arrangements outperform deteriorating fee-for-service in a rate-down environment.
The V28 phase-in and the 2027 physician pay cut [189] create near-term EBITDA pressure on any target whose revenue is predominantly MA-capitated or MIPS-dependent. Diligence for any VBC-adjacent deal must include a waterfall of V28 phase-in impact on the target's 2026 and 2027 benchmark revenue, and a MIPS sunset sensitivity. VBC enablers with diversified payer mix (commercial + Medicare FFS + MA) are structurally more defensible than pure-play MA capitation plays in this rate environment.
Policy on the radar.
When public-market bonds yield 5.24% risk-free, allocators rightly demand a credible 15–20% net IRR from a healthcare PE fund to justify the illiquidity premium — and they should. The counterintuitive point: a high-rate environment culls weak PE sponsors who over-levered at low rates and are now managing zombie portfolios, while validating operator-led funds that underwrote conservatively and earn returns through EBITDA growth rather than multiple expansion. The most compelling LP argument in this rate environment is a deal portfolio where exit multiple can be flat or down and the fund still returns 2.5x+ on a 5-year hold — because EBITDA was built, not borrowed. That argument lands better at 5.24% 10Y than it did at 1.5%, because the math on what operational alpha looks like versus treasuries is now vivid.
Public-market healthcare repricing almost always over-shoots the policy reality for large-cap names, and the current move is driven by MA plan margin fear (V28, benchmark cuts) that does not transmit directly to LMM home health, 340B pharmacy, or RCM automation companies. The spread between public-market healthcare sentiment (XLV −2.65% in one week [38][45]) and private LMM deal multiples (historically high, slow to adjust [108]) represents a structural inefficiency that specialist investors exist to exploit. When XLV is selling off, strategic acquirers in healthcare are distracted, leverage is tight, and smaller operators are more willing to engage with a fund that offers operational partnership rather than a financial recap. This is the sourcing environment, not the exit environment.
Whether manufacturers win or covered entities win the contract-pharmacy legal battle is a binary outcome that neither side controls. But both sides converging on a data clearinghouse as the structural solution [168] means the data-infrastructure market is validated regardless of the legal outcome — the clearinghouse gets built either as an HRSA mandate (covered-entity win) or as a manufacturer compliance tool (manufacturer win). The picks-and-shovels vendors building HRSA-audit-ready claims platforms are going to be needed in both scenarios. The 340B thesis lane is most defensibly scoped to the data infrastructure layer, not the covered-entity operator layer, precisely because the infrastructure demand is outcome-agnostic.
Oura's Nasdaq delay [66][67][69] and accelerating Q3 IPO postponements [65][68] mean that venture-backed digital health companies that raised at 2021 valuations are now in a no-exit limbo — their VC sponsors need liquidity, their public path is closed, and strategic acquirers are disciplined on price. Some of these companies have built genuine clinical workflow assets (ambient documentation, prior-auth automation, care-coordination infrastructure) that are worth owning at a reset valuation. A systematic secondary-market screen of late-stage digital health companies whose last venture round implied a valuation now 40–60% below current comparable private transaction comps is the opportunity. The healthcare AI funding tracker [204][205][213] provides the starting universe.
Operators that built EBITDA expansion stories on PDGM-favorable coding between 2020 and 2023 are now facing a multi-year recalibration that erodes their margin without any operational deterioration. For a sub-scale agency owner in year four of a business built post-PDGM implementation, the combination of recalibration headwinds, rising borrowing costs, and compliance complexity from state PE reporting laws [195] creates a genuine motivation to sell that did not exist when the reimbursement tailwind was running. This is the specific moment — post-recalibration awareness, pre-final-rule clarity on CY2027 — when owners are maximally motivated and buyers who understand the PDGM mechanics can structure deals that price the recalibration risk correctly while offering certainty-of-close. Diligence capability on PDGM cohort analysis is a competitive sourcing advantage in this window.
Six themes we expect to shape lower middle market healthcare over the coming quarter.
Disclaimer. This material is provided by Breaking Wave Capital for informational and discussion purposes only. It is not an offer to sell or a solicitation of an offer to buy any security or interest in any fund, and no such offer will be made except by means of a confidential private placement memorandum and only in jurisdictions where permitted by law. Nothing herein is investment, legal, tax or accounting advice, and it does not take account of any recipient's objectives, financial situation or particular needs. Views on markets, sectors and transactions are as of the date shown and may change without notice. Third-party information is believed to be reliable but has not been independently verified. Targets, estimates and forward-looking statements are not guarantees of future results; past performance does not indicate future performance, and any investment involves risk, including the possible loss of capital.
WEEKLY MEMO · WEEK OF OCTOBER 5, 2026
PAST / PRESENT The week ending October 8 delivered a bifurcated tape that tells a precise story about where institutional conviction is sitting: the S&P 500 (SPY) gained +1.16% to 778.57 and the Dow (DIA) added +0.98% to 516.11, but the divergence is in the tails [17][40][41]. The Nasdaq 100 (QQQ) crept only +0.23% to 751.27 — AI-driven megacap momentum is stalling as rates bite — while the Russell 2000 (IWM) fell -0.92% to 278.94, a clean read that small-cap credit sensitivity is being punished in a 10Y-at-5.22% environment [18]. The standout: S&P Health Care (XLV) surged +2.79% to 170.81, the week's sector leadership winner by a wide margin, with 30% of S&P 500 healthcare constituents printing new highs on the week [46]. That is not momentum chasing; it is defensive rotation, confirmed by Morningstar's weekly noting utilities also rising while industrials fell [41]. The rates complex gave a fractional reprieve — 2Y Treasuries eased 3bp to 4.75%, 10Y fell 2bp to 5.22%, 30Y slipped 1bp to 5.60% — but the 2s10s spread remains a positive 47bp, and the Fed's September minutes (released this week per ABC News/WSJ [49][51]) explicitly flagged another hike is likely before year-end, with markets now bracing for additional increases into 2027 [47]. The Fed funds target moved to 3.75%–4.00% at the September meeting — the first hike since 2023 [55][56] — and CME FedWatch is pricing a non-trivial probability of a follow-on. MarketWatch ran an explicit scenario piece on how 10Y yields reach 6% without a market crisis [18]; that is now the tail risk that must be underwritten against, not dismissed. Bank earnings — JPMorgan, Wells Fargo, Citi — are the next catalyst, with the Street watching for net interest margin commentary on what higher-for-longer actually does to commercial loan books [16][57]. AHEAD Q3 earnings season opens in earnest; CPI and bank NIM commentary will either validate or break the "soft landing with higher rates" consensus that is currently holding XLV at these levels.
| INDEX | LEVEL | WK |
|---|---|---|
| S&P 500 (SPY) | 778.57 | +1.16% |
| Dow Jones (DIA) | 516.11 | +0.98% |
| Nasdaq 100 (QQQ) | 751.27 | +0.23% |
| Russell 2000 (IWM) | 278.94 | -0.92% |
| S&P Health Care (XLV) | 170.81 | +2.79% |
| INSTRUMENT | LEVEL | NOTE |
|---|---|---|
| 2Y Treasury | 4.75% | -3bp w/w |
| 10Y Treasury | 5.22% | -2bp w/w |
| 30Y Treasury | 5.60% | -1bp w/w |
| 2s10s | +47bp | positive |
Sector leadership: Healthcare ran the table this week [41][46]. The defensive/dividend rotation that lifted utilities is the same capital flow lifting XLV — investors are buying earnings visibility and reimbursement-backed cash flows in a world where the risk-free rate is 5.22%. The message is unambiguous: public market institutions are paying up for exactly the cash-flow profile that Breaking Wave Capital's thesis lane companies carry.
| INDEX | LEVEL | WK |
|---|---|---|
| Korea (EWY) | 177.24 | -7.63% |
| China (FXI) | 34.24 | +3.16% |
| Japan (EWJ) | 97.86 | -1.07% |
| Europe (VGK) | 86.03 | -0.41% |
| Germany (EWG) | 40.96 | -0.82% |
| UK (EWU) | 46.52 | +0.74% |
| ASSET | LEVEL | WK |
|---|---|---|
| WTI crude | 96.24 | +0.08% |
| Brent crude | 125.44 | +10.07% |
| Natural gas (UNG) | 11.01 | +5.16% |
| Gold (GLD) | 384.58 | +1.17% |
| Silver (SLV) | 54.78 | +0.07% |
| Copper (CPER) | 40.31 | +2.00% |
| Platinum (PPLT) | 15.25 | -1.17% |
| Wheat (WEAT) | 24.41 | -1.37% |
| Corn (CORN) | 18.42 | -2.28% |
| DXY (UUP) | 29.02 | +0.45% |
| EUR/USD | 1.1206 | -0.17% |
| USD/JPY | 158.25 | +0.37% |
| Bitcoin | 82,987.71 | -2.07% |
The international tape this week was a tale of two risk regimes. Korea (EWY) cratered -7.63% to 177.24 — the SK Hynix earnings miss triggering a second-day chip rout that Stocktwits flagged as KORU's worst monthly decline [143] — while China (FXI) rebounded +3.16% to 34.24 on the back of the China-EU hybrid vehicle deal announced October 9 [30][163][165]. Europe (VGK) fell -0.41% and Germany (EWG) -0.82%, consistent with Bloomberg's reporting that Europe's indebted sovereigns are blinking at bond market pressure [12]; UK (EWU) bucked the trend at +0.74%, likely reflecting sterling's relative stability. On commodities: Brent crude spiked +10.07% to $125.44 — an extraordinary weekly move driven by Hormuz transit risk and Houthi attacks on Saudi infrastructure [7][19][137] — while WTI was nearly flat at $96.24 (+0.08%), a spread that reflects physical routing disruptions rather than aggregate demand. Gold (GLD) added +1.17% to $384.58, a classic geopolitical hedge. The dollar (UUP) firmed +0.45% as the DXY held near 29.02, with EUR/USD slipping to 1.1206 and USD/JPY pushing to 158.25. The strong dollar combined with a 5.22% 10Y creates currency drag for foreign capital in dollar-denominated funds, and any portfolio company with Asian API or generic sourcing exposure sees input cost pressure as the yen weakens further. The Brent-WTI spread and the Korea chip rout together signal that supply-chain fragmentation — not just demand — is driving commodity volatility, which feeds directly into the inflation path that governs the cost of leverage.
THE WEEK'S FLASHPOINTS
HEADLINE RISK The week's most instructive case study in headline-driven mean reversion is the Trump-Iran sequence: Trump's no-strike pledge moved oil modestly lower intraday on October 9 [135][139], but Brent ended the week +10.07% as implemented policy — the shadow fleet sanctions [164] and Houthi attacks [19] — continued to operate independently of the statement. The Trump-Putin diesel deal produced the inverse dynamic: a policy announcement that should ease supply concerns was immediately complicated by sanctions-law questions [153][156], leaving Brent essentially unmoved on the news. The analytic discipline here is the same in both directions: headline-driven moves mean-revert; implemented sanctions, physical disruptions, and treaty obligations do not. Underwriting must be anchored to the latter. Similarly, the Canada tariff escalation-then-negotiation cycle [152][155] produced a brief dollar strengthening that has already partially faded; the structural trade disruption, however, is real and will compound over quarters.
READ-THROUGH FOR THE LMM The Hormuz/Brent story is the most direct link to cost of capital: Brent at $125.44 feeds into a US inflation print that keeps the Fed hawkish, which keeps the 10Y at or above 5.22%, which is the rate against which every new deal must be priced. The connection is indirect but mechanically sound. On supply chains: generic pharmaceutical API sourcing from China and India creates exposure to both US-China trade friction and the dollar/yen dynamic — companies with API concentration in single Asian geographies carry unpriced risk that diligence must surface. The Korea chip selloff is relevant to healthtech valuations indirectly: AI infrastructure cost and semiconductor availability affect the build-vs-buy calculus for RCM and clinical AI platforms.
| METRIC | READING | READ-THROUGH FOR BWC |
|---|---|---|
| Healthcare PE deal value '25 | Record $191B disclosed globally (Bain/Business Journals, Oct 2026) [106][218] | Validates thesis lanes; megafund concentration means LMM remains underserved |
| Concentration (Q1 '26) | eHealth captured 61% of disclosed deal value in Q1 '26 despite 29% deal count decline (PwC) [82] | Healthtech/digital dominates value; services LMM is less competitive, better priced |
| LMM healthcare multiples | Sub-$10M EBITDA services historically elevated; mid-market funds raised ~$59B since 2022, +40% vs prior 3Y [111] | Entry multiples for LMM targets remain below megafund comp levels; operator-led sourcing is the credible wedge |
| LMM deal flow (Axial) | Top-50 LMM healthcare investor list active; new transactions on Axial platform up 60% in comparable prior period [109] | Sourcing volume is robust; selectivity and speed-to-IOI are the differentiators |
| US IPO exits '25–'26 | IPO selectivity high; investors focused on valuation, profitability, differentiation (PwC Q3 '26) [76]; Oura pulled IPO citing valuation/Apple threat [71]; Firmus scrapped Australian IPO [67] | Exit via IPO remains narrow; trade sale and sponsor-to-sponsor are primary exit paths for current vintage; plan accordingly |
| Family-office appetite | ~40% of FOs plan to raise private equity allocations; 42% already in alternatives; 34% >40% in privates (Goldman Sachs, Hamilton Lane) [118][121] | Family-office LP appetite is correctly targeted toward healthcare-focused LMM managers; liquidity concerns [113] mean co-invest structures and shorter J-curve narratives outperform in current conversations |
| Dry powder / secondaries | Mid-market healthcare funds raised ~$59B since 2022 [111]; Sheridan Capital closed $1.35B across Fund IV ($1.1B) and Healthcare IT Fund ($245M) this week [81][107]; Aphias closed $1.05B debut [105] | Competitive but not saturated at LMM; Sheridan's Healthcare IT fund confirms AI/RCM as a standalone institutional thesis — validates the healthtech lane analysis in §7 |
The private market barbell is now clearly defined: at the top, megafunds and large specialists (Sheridan at $1.35B [81][107], Bain's record $191B deployment year [218]) are running concentrated, AI-adjacent and physician-practice platform strategies at scale. At the bottom, genuine LMM operators — sub-$10M EBITDA healthcare services — remain thinly covered by institutional capital. The Q1 '26 PwC data [82] makes this concrete: 61% of deal value concentrated in eHealth despite a 29% drop in deal count means fewer, larger checks are chasing digital assets, leaving the services LMM comparatively quiet. McKesson and a private equity firm buying Option Care Health [181] and Harbor Health acquiring 27 Village Medical clinics [179] are the mid-market consolidation moves that define the competitive ceiling above the LMM — these are the roll-up comps that exit buyers will reference.
THE READ Sheridan's simultaneous close of a $1.1B generalist healthcare fund and a standalone $245M Healthcare IT vehicle [81][107] is the week's clearest fundraising signal. Institutional LPs are writing healthcare-specific checks at scale, and dedicated capital is now aimed at the revenue-cycle and AI layer. Aphias' $1.05B debut close [105] shows that operator-led healthcare managers can raise capital in this environment.
The headline mechanics. MedPAC formally launched a PDGM study analyzing home health payment accuracy on October 9, 2026 [192] — the most significant home health regulatory development of the week. MedPAC's mandate is to evaluate whether PDGM payment rates accurately reflect the cost of care; the last time MedPAC ran this analysis at scale, it produced the behavioral adjustment clawbacks that shaved margins across the sector. The CY 2026 HH PPS final rule (CMS-1828-F) is in effect [195][196], and CMS has already issued a CY 2027 proposed rule fact sheet (CMS-1844-P) [194] that operators must model now. The 2027 proposed rule continues the PDGM 30-day payment unit structure implemented January 1, 2020 [197] and carries forward the annual behavioral adjustment methodology. CMS simultaneously announced a moratorium on new hospice and home health providers accepting Medicare — a supply-side freeze that directly benefits existing licensed operators and is underappreciated in current valuation conversations [189].
The PDGM behavioral-adjustment machinery. MedPAC's new study [192] is the upstream policy event that will determine whether CMS recalibrates the behavioral adjustment in the 2027 final rule (due November/December 2026). The mechanism: if MedPAC finds agencies systematically coding into higher-paying PDGM categories beyond what clinical acuity justifies, CMS uses a prospective behavioral adjustment — a rate reduction applied across the board — to claw back projected overpayment. For a $5M EBITDA home health operator, a 1% net rate change translates directly to ~$500K in EBITDA sensitivity before any margin offset. The CY 2026 final rule is already enacted [195][196]; the 2027 proposed rule is the live risk.
Second-order effects.
Breaking Wave's thesis in this lane centers on home-health consolidation: acquiring and operationally integrating licensed Medicare-certified agencies in underserved geographies, with particular attention to the double-moat profile created by the federal enrollment moratorium and state certificate-of-need laws. MedPAC's PDGM study launch [192] is a binary event for any home health asset under evaluation in the next 90 days. If MedPAC's findings support a downward behavioral adjustment in the 2027 rule, current multiples need a 100–200bp EBITDA haircut in the base case. Conversely, if MedPAC validates payment accuracy, moratorium-protected licensed operators become significantly more valuable. The analytically sound posture is to run PDGM sensitivity analysis on every services target before advancing to a formal offer, and to use the moratorium point [189] as a valuation lever in any asset carrying existing licensure.
Specific PDGM behavioral-adjustment magnitude for the 2027 proposed rule, and MedPAC study preliminary findings, are not yet public as of October 8, 2026.
Contract-pharmacy restrictions. The 340B contract-pharmacy litigation front remains active and jurisdiction-dependent. The D.C. Circuit upheld manufacturer restrictions on contract-pharmacy dispensing [176]; the Third Circuit similarly allowed restrictions [178]; the Fourth Circuit blocked West Virginia's state-level contract-pharmacy protection law [175]. The net legal posture as of this week: manufacturers have federal appellate cover to restrict contract-pharmacy access in most circuits, and state legislative workarounds are being invalidated. Modern Healthcare (October 1) reported directly on how this fight is squeezing rural hospitals and clinics [172], with covered entities losing 340B margin on contract-pharmacy dispensed units — the exact revenue stream that funds cross-subsidized services. The JDSupra analysis [173] argues academic medical centers and large health systems have the most absolute-dollar exposure, but the percentage-of-revenue hit is sharpest at rural critical access hospitals and federally qualified health centers that lack the scale to absorb it.
The Rebate Model Pilot. The HRSA rebate model pilot — under which manufacturers provide 340B discounts via post-purchase rebates rather than upfront pricing — remains a structural threat to contract-pharmacy-dependent covered entities. The pilot shifts the timing and certainty of the 340B discount, creating cash-flow volatility for covered entities that have built cost structures around upfront drug cost savings. The litigation trajectory [174][175][176][178] is directionally reducing the enforceability of the upfront-price model that covered entities prefer.
Breaking Wave's thesis in this lane is explicitly picks-and-shovels: the compliance and audit infrastructure layer that covered entities must build regardless of which legal regime prevails. As manufacturers restrict contract pharmacies and HRSA scrutinizes covered entity eligibility, the demand for 340B compliance software — patient eligibility verification, claims accumulation, audit trail management — is structural and growing. Named vendors active in this space include Verity Solutions (contract-pharmacy management), Kalderos (manufacturer-side compliance and rebate reconciliation), and RxStrategies (covered entity compliance software). The category generates recurring revenue independent of which side wins the litigation. Harbor Health's acquisition of 27 Village Medical clinics [179] — creating a larger covered-entity footprint — is exactly the kind of consolidation that increases the dollar value of 340B compliance infrastructure per acquiring entity, and is representative of the demand dynamic Breaking Wave is underwriting in this lane.
Specific Q3 2026 340B revenue impact figures for named rural hospitals and the precise timeline for any HRSA rebate model pilot expansion are not confirmed in this week's public evidence.
RCM adoption reality. The contradiction at the center of RCM AI adoption in 2026: Capstone Partners reported a 93.8% surge in AI-enabled healthcare IT M&A [200], yet Procode — a billing platform that just hired Blair Baker, Optum's former RCM Innovation CIO, as of October 6 [199] — is explicitly scaling because the market is still deeply fragmented and under-automated. The adoption rate for AI-enabled prior authorization and denial management tools at LMM physician practices and home health agencies remains well below the headline penetration numbers that large health system surveys report. The gap between "large system AI adoption" and "LMM practice AI adoption" is the market Breaking Wave is underwriting. RCM companies on Vertess' analysis [201] are being positioned for a 2026 M&A boom by owners strengthening recurring revenue, diversifying client bases, and optimizing EBITDA margins — exactly the pre-sale value creation playbook that well-positioned operators should be running.
Funding & the two-tier market. AI captured 80%+ of venture capital through Q3 2026 [100], with US funding climbing 13% QoQ and holding 57% of global VC share [99]. But within healthtech, the split is sharp: Pearl Health raised $110M in debt and equity to build out its AI platform for primary care [213]; HealthLeap raised $38M for AI patient monitoring [208]; Vitalize raised $31M for healthcare staffing AI [210]; Arintra and Happy Health captured smaller rounds [206]. The top of the market is large rounds for AI-native platforms with durable clinical workflow integration. Below that: seed and Series A rounds for GPT-wrapper tools that automate a single billing or prior auth step. Forbion bucked VC fundraising trends by closing €2.3B across two new funds [97], confirming that European life sciences capital is also concentrating at scale. The two-tier dynamic means LMM RCM and healthtech companies that cannot demonstrate workflow-level integration — not just API call efficiency — are being marked down at Series A.
Moats vs. commoditization. The durable-moat companies in RCM AI share a structural feature: they sit inside the EHR workflow, not outside it. R1 RCM (the largest acquirer in the space since 2019 per Scope Research [205]), Innovaccer (which has made recent M&A moves [202]), and IKS Health (recent deal activity [202]) have built integration depth that GPT-wrapper point solutions cannot replicate without 12–18 months of EHR negotiation. Teladoc's AI feature launch this week [209] is an example of a large incumbent adding AI capability defensively — not a moat builder, a moat defender. The commoditization risk is real at the prior-authorization automation layer, where at least a dozen funded startups are competing on the same CMS API feeds. The Breaking Wave lens for any RCM target: EHR integration depth, payer contract connectivity, and denial-appeal win rate are the three metrics that distinguish a durable platform from a feature being built by the incumbents.
Specific EBITDA multiples for named RCM companies are not confirmed in this week's public evidence.
Medicare Advantage & VBC. The MA and value-based care environment is being reshaped by three simultaneous pressures that operators must hold in mind together. First, the V28 risk-score model phase-in is compressing MA plan medical loss ratios by reducing the risk-adjusted payments for chronic condition coding that plans have relied on — this is why Humana and CVS/Aetna have been pulling back from certain MA markets and why the Aetna earnings reference in Morningstar's sector tracker [65] flagged price pressure growing with oral cash-pay success. Second, the benchmark rate environment for MA plans is structurally tighter; plans that cannot demonstrate competitive Stars ratings are losing enrollment to peers. Third, named VBC enablers — Privia Health, Agilon Health, and Oak Street Health (now inside CVS) — are experiencing margin pressure from the same V28 dynamics that squeeze the plans, because capitation rates flow through plan benchmarks. Pearl Health's $110M raise [213] to scale its AI platform for primary care is a direct bet that the VBC enabler layer can use AI to recover the margin lost in V28 recalibration.
Breaking Wave's positioning is not in the MA plan layer or the large VBC enabler layer — it is in the services companies that VBC enablers need to operate: home health, behavioral health, and 340B-eligible specialty pharmacy. As MA plans retrench from high-cost geographies [85], the fee-for-service and Medicaid-waiver backstop for home health and 340B-eligible pharmacy becomes more important, not less. The underwriting advantage lies in understanding the reimbursement floor — Medicare FFS home health rates, 340B drug pricing — that exists below the MA capitation layer and is structurally insulated from MA plan volatility.
Policy on the radar.
CMS's freeze on new hospice and home health provider enrollment [189] is being read as a regulatory burden story. It is the opposite: it is a certificate-of-need equivalent without the legislative overhead. Every licensed home health agency underwritten today carries an embedded regulatory moat that a new entrant cannot replicate until the moratorium lifts. At current LMM multiples, that moat is not in the price. The opportunity: licensed home health operators with existing Medicare provider numbers in certificate-of-need states carry a double-moat profile — state CON plus federal moratorium — that justifies a premium to current market multiples that can be defended rigorously on fundamentals.
Brent at $125.44, WTI at $96.24 — a $29 spread driven by Hormuz routing disruptions [7][137] — is not a demand story; it is a supply-chain fragmentation story that feeds directly into US import prices and CPI. The Fed minutes already signal another hike [49][51]; a sticky CPI print driven by energy and import costs makes November a live meeting. Every leveraged buyout underwritten at 2024 debt economics needs to be re-run at 5.5%–6.0% cost of debt. Healthcare services with reimbursement-backed revenue — Medicare PPS rates, 340B drug cost savings — are the only LMM asset class where EBITDA does not correlate with energy prices. The pitch is not "healthcare is defensive" (generic); it is "healthcare reimbursement is the only cash flow in the LMM that the Fed cannot reach."
When a specialist raises a dedicated sub-fund for a sub-sector, it means competition for deals in that sub-sector is about to intensify materially. Sheridan's $245M Healthcare IT vehicle [81][107] will be writing checks into the same RCM, clinical AI, and health data companies that Breaking Wave sources in its healthtech lane. The contrarian read: this is the signal to prioritize healthcare services — home health, 340B pharmacy — where Sheridan's IT fund cannot compete, and to position Sheridan's fund as the "strategic acquirer" narrative in exit-path conversations, not as a reason to accelerate into the same healthtech deal flow they are chasing.
When M&A volume surges 93.8% in a category, the marginal deal being done is not the best deal — it is the deal that couldn't get done at last year's standards. The acquirers in the Capstone Partners report [200] are buying workflow-adjacent AI features to defend existing market positions, not to create new ones. The RCM AI companies being acquired at the margin are precisely the GPT-wrapper features that should be avoided as portfolio targets — because strategic buyers are acquiring them to eliminate them as standalone competitors, not to scale them. The durable acquisition targets are the EHR-integrated platforms that strategics cannot build organically; those are the sourcing priorities worth pursuing with discipline.
SK Hynix's earnings miss and the KORU ETF's worst monthly decline [143][148] are not isolated Korea stories — they are the semiconductor supply constraint that will slow the cost-curve decline for AI compute infrastructure. If AI compute costs do not fall at the pace that 2024–2025 healthtech underwriting assumed, the unit economics of AI-native RCM and clinical decision support platforms deteriorate. Companies that raised at 20x+ ARR on the assumption of continued AI compute cost deflation are now carrying valuation marks that assume a cost structure that may not materialize. The diligence question for every AI-adjacent healthtech target: what is the compute cost as a percentage of gross margin today, and what does it look like if GPU costs stay flat for 24 months?
Five themes we expect to shape lower middle market healthcare over the coming quarter.
Disclaimer. This material is provided by Breaking Wave Capital for informational and discussion purposes only. It is not an offer to sell or a solicitation of an offer to buy any security or interest in any fund, and no such offer will be made except by means of a confidential private placement memorandum and only in jurisdictions where permitted by law. Nothing herein is investment, legal, tax or accounting advice, and it does not take account of any recipient's objectives, financial situation or particular needs. Views on markets, sectors and transactions are as of the date shown and may change without notice. Third-party information is believed to be reliable but has not been independently verified. Targets, estimates and forward-looking statements are not guarantees of future results; past performance does not indicate future performance, and any investment involves risk, including the possible loss of capital.
Tell us who you are and the mandate you invest against. Accreditation is verified before any materials are released — nothing here is an offer to sell securities.
Attach the deck or paste a data-room link. It is logged, filed and given a structured first read the day it arrives — every deck, no exceptions.